![conference banner](/images/conference-banner.jpeg)
Abstract
Gait is a complex motor task, initiated and governed by different areas of the brain. Studies have shown a clear association between gait and cognition. Impairments in both gait and cognition are prevalent in older adults. Older adults with gait impairment have an increased risk of developing cognitive impairments. Those with cognitive impairment often have gait impairments and more falls than cognitively healthy older adults. Recent studies have shown that quantitative gait analysis, particularly performed during dual task conditions, can detect gait deficits that cannot yet be seen by the naked eye, even to a trained specialist. Some studies have shown that such gait disturbances were measurable years before mild cognitive impairment or dementia or walking difficulties were clinically manifest. Quantitative gait analysis can provide early detection of gait and cognitive impairments as well as fall risk. Future quantitative gait studies may help distinguish dementia subtypes in early stages of the diseases. Early detection of gait and cognitive impairments would provide a better understanding of disease pathophysiology and progression. Early detection also allows the timely implementation of interventions with the ultimate goal of improving or maintaining mobility and functional independence for as long as possible. Quantitative gait analysis should be viewed as a clinical tool to aid diagnoses and treatment planning. This review examines the current literature on quantitatively measured gait impairment in older adults with mild cognitive impairment or a dementia subtype.
Keywords: Quantitative gait analysis, neuromotor control, gait control, gait deficits, cognitive impairment, dementia, dual task, older adults, aging.
Current Pharmaceutical Design
Title:Quantitative Gait Disturbances in Older Adults with Cognitive Impairments
Volume: 20 Issue: 19
Author(s): Stephanie A. Bridenbaugh and Reto W. Kressig
Affiliation:
Keywords: Quantitative gait analysis, neuromotor control, gait control, gait deficits, cognitive impairment, dementia, dual task, older adults, aging.
Abstract: Gait is a complex motor task, initiated and governed by different areas of the brain. Studies have shown a clear association between gait and cognition. Impairments in both gait and cognition are prevalent in older adults. Older adults with gait impairment have an increased risk of developing cognitive impairments. Those with cognitive impairment often have gait impairments and more falls than cognitively healthy older adults. Recent studies have shown that quantitative gait analysis, particularly performed during dual task conditions, can detect gait deficits that cannot yet be seen by the naked eye, even to a trained specialist. Some studies have shown that such gait disturbances were measurable years before mild cognitive impairment or dementia or walking difficulties were clinically manifest. Quantitative gait analysis can provide early detection of gait and cognitive impairments as well as fall risk. Future quantitative gait studies may help distinguish dementia subtypes in early stages of the diseases. Early detection of gait and cognitive impairments would provide a better understanding of disease pathophysiology and progression. Early detection also allows the timely implementation of interventions with the ultimate goal of improving or maintaining mobility and functional independence for as long as possible. Quantitative gait analysis should be viewed as a clinical tool to aid diagnoses and treatment planning. This review examines the current literature on quantitatively measured gait impairment in older adults with mild cognitive impairment or a dementia subtype.
Export Options
About this article
Cite this article as:
Bridenbaugh A. Stephanie and Kressig W. Reto, Quantitative Gait Disturbances in Older Adults with Cognitive Impairments, Current Pharmaceutical Design 2014; 20 (19) . https://dx.doi.org/10.2174/13816128113196660688
DOI https://dx.doi.org/10.2174/13816128113196660688 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?
CNS & Neurological Disorders - Drug Targets Mechanisms of Cell Signaling and Inflammation in Alzheimers Disease
Current Drug Targets - Inflammation & Allergy Study on Multi-Target Synergistic Treatment of Alzheimer’s Disease Based on Metal Chelators
Current Drug Targets “Care-Getting”: A Conceptual Model of Marshalling Support Near the End of Life
Current Aging Science Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome
CNS & Neurological Disorders - Drug Targets Brain Perfusion In Sepsis
Current Vascular Pharmacology Sports-Related Brain Injury and Neurodegeneration in Athletes
Current Molecular Pharmacology Cognitive Impairment with Vascular Impairment and Degeneration
Current Neurovascular Research Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Cognitive, Psychological and Psychiatric Effects of Ionizing Radiation Exposure
Current Medicinal Chemistry The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence
Current Alzheimer Research Cerebrovascular Changes and Neurodegeneration Related to Hyperlipidemia: Characteristics of the Human ApoB-100 Transgenic Mice
Current Pharmaceutical Design Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Bottom-Up Proteomics
Current Analytical Chemistry Pathogenesis of Alzheimer Disease: Role of Oxidative Stress, Amyloid-β Peptides, Systemic Ammonia and Erythrocyte Energy Metabolism
CNS & Neurological Disorders - Drug Targets Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design Synthesis and Biological Activity of New 2,3-dihydro-1H-cyclopenta[b]- quinoline Derivatives as Acetylcholinesterase Inhibitors
Letters in Drug Design & Discovery Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
Current Drug Targets To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets